#None #healthcare #Alfresa #AI KEN PHARMA

Strategic Collaboration for Healthcare in Southeast Asia

In an exciting development, a new partnership has begun between AI KEN PHARMA ASIA PACIFIC HOLDINGS PTE.LTD. and a Japanese company aimed at enhancing healthcare in Southeast Asia. This partnership looks to focus primarily on the wholesale distribution of medical pharmaceuticals, beginning with negotiations for capital business alliances.

Background and Objective

The company has a rich history in overseas ventures, particularly in Vietnam where they established a joint venture named Alfresa Codupha Healthcare Vietnam Co., Ltd. in November 2013. The aim of this venture was to introduce new products and services to improve healthcare outcomes while facilitating the import and sale of healthcare-related products, primarily medical devices and materials. This strategy aligns with their long-term vision, identified in their mid-term management plan titled “Vision2032 Stage2 - Shaping the Future with Comprehensive Strength.”

The vision emphasizes the evolution of their Asian business strategy aimed at enhancing collaborations with overseas enterprises. In particular, their goal is to set up full agency operations for pharmaceutical companies by managing the registration, import, distribution, marketing, and sales of medical drugs and devices locally.

On the other hand, AI KEN PHARMA, which aims to act as a bridge between Japanese healthcare needs and the Southeast Asian market, carries out full agency operations in various countries, including Laos and Cambodia. With special expertise in oncology and gastroenterology, AI KEN PHARMA brings valuable insights into expanding healthcare capabilities in the region.

Through this agreement, both companies will leverage their knowledge and experiences as they aim to expand AI KEN PHARMA's operations throughout Southeast Asia. This collaboration is anticipated to improve the sales channels for Japanese pharmaceutical companies, contributing positively to local healthcare quality and accessibility.

Collaboration Details

The focus of the partnership will also include the development of pharmaceutical business opportunities in Vietnam and providing joint proposals to Japanese pharmaceutical and medical device manufacturers looking to enter the Southeast Asian market. This initiative further solidifies the commitment of both parties to nurture healthcare advancements and expand their market reach collaboratively within the region.

Future Outlook

While the short-term impact of this partnership on the current fiscal year (ending March 2026) is expected to be minimal, it is believed that this strategic alliance will enhance the long-term corporate value of both companies. Both entities plan to keep stakeholders updated on any significant developments that may arise from this collaboration.

For further information, please visit the websites of the companies involved: Alcopha and their respective project updates on corporate strategies. With this partnership, both companies look forward to a future marked by enhanced healthcare services and innovation in the Southeast Asian market.